---

Jean-Paul Clozel

Founder and Chief Executive Officer, Actelion

After eleven years as a clinician, Jean-Paul decided to move to applied research – spending 12 years at F. Hoffmann-La Roche, during which time he was responsible for the selection of the first T-channel blocker. He has built Actelion from a start-up to a multi-billion market capitalization company.

---

Part of the Power List 2016

The Top 100

The nominations are in and after considerable debate and analysis from our judging panel, we present The Power List 2016 – our second foray into the Top 100 most influential people in the world of drug development and manufacture.

Go to The Power List 2016